Total abdominal colectomy, pelvic peritonectomy, and end‐ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non‐gynecologic cancer

Stamou, Konstantinos M.; Karakozis, Stavros; Sugarbaker, Paul H.

doi:10.1002/jso.10270

Cited by 11 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is the reason why 8 subtotal colectomies were performed in the present study. This aggressive method has been successfully used for the treatment of mucinous peritoneal carcinomatosis from nongynecologic cancer [16]. Therefore, high rate of complete (69.8%) or near-complete cytoreduction (25.6%) was possible although in 20 patients the PCI was >15 which is in agreement with other reports for patients with primary or recurrent ovarian cancer [7–9, 11, 14, 17, 18].…”

Section: Discussionsupporting

confidence: 79%

Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer

Tentes¹,

Kakolyris

Kyziridis³

et al. 2012

Journal of Oncology

View full text Add to dashboard Cite

Background/Aims. Intraperitoneal intraoperative hyperthermic chemotherapy (HIPEC) has been used in the treatment of ovarian cancer. The purpose of the study is to determine the efficacy of HIPEC after cytoreductive surgery in advanced ovarian cancer. Patients/Methods. From 2006 to 2010 patients with advanced ovarian cancer were enrolled in a prospective nonrandomized study to undergo cytoreductive surgery combined with HIPEC. Clinical and histopathological variables were correlated to hospital mortality, morbidity, survival, and recurrences. Results. The mean age of 43 women was 59.9 ± 13.8 (16–82) years. The hospital mortality and morbidity rate were 4.7% and 51.2%, respectively. Complete cytoreduction was possible in 69.8%. The overall 5-year survival rate was 54%. The prognostic indicators of survival were the extent of prior surgery (P = 0.048) and the extent of peritoneal dissemination (P = 0.011). The recurrence rate was 30.2%. Conclusions. Maximal cytoreductive surgery combined with HIPEC is a well-tolerated, feasible, and promising method of treatment in advanced ovarian cancer.

show abstract

Section: Discussionsupporting

confidence: 79%

Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer

Tentes¹,

Kakolyris

Kyziridis³

et al. 2012

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…Even with large volumes of cancer recurrence, the accumulation of cancer-causing obstruction can be found at three specific anatomic sites. These are the gastric outlet, the terminal ileum and ileocecal valve region, and the rectosigmoid colon [22]. In patients with a good performance status, aggressive resection of localized disease may offer considerable benefit with acceptable risk.…”

Section: Patient Selection For Palliative Surgerymentioning

confidence: 98%

“…Major exploratory surgery should be avoided if at all possible, for these patients have a limited survival of ~6 months [20][21][22]. Table 2 provides the stop signals for surgical palliation of advanced primary or recurrent gastrointestinal cancer.…”

Section: Patient Selection For Palliative Surgerymentioning

confidence: 99%

Peritoneal surface oncology: review of a personal experience with colorectal and appendiceal malignancy

Sugarbaker

2005

Tech Coloproctol

View full text Add to dashboard Cite

Peritoneal surface malignancy usually results from implantation of gastrointestinal cancer. In the past, this clinical situation was treated with palliative intent. A definitive approach to peritoneal surface malignancy involves peritonectomy procedures, visceral resections, perioperative intraperitoneal chemotherapy and knowledgeable patient selection. The quantitative prognostic indicators necessary for valid clinical judgements include the cancer histopathology (invasive vs. expansive progression), the preoperative abdominal and pelvic CT, the peritoneal cancer index and the completeness of cytoreduction score. Proper patient selection is mandatory for optimizing the results of treatment. In a series of phase II studies, appendiceal tumors with peritoneal seeding became the paradigm for success with an 85% long-term survival in selected patients. Carcinomatosis from colon cancer had an overall 5-year survival of 45% with selected patients. In all malignancies, early aggressive treatment of minimal peritoneal surface dissemination showed the greatest benefit. The definitive prognostic indicator was the complete cytoreduction. Oncologists must seek new knowledge regarding the management of peritoneal surface dissemination of cancer because a curative approach has been demonstrated in large phase II studies; in contrast all historical controls show 0% long-term survival. Additional adjuvant phase III studies with perioperative intraperitoneal chemotherapy in diseases where peritoneal surface spread occurs are indicated.

show abstract

“…Total gastrectomy is infrequently required in an attempt to achieve complete cytoreduction. Segmental intestinal resection or subtotal colectomy with endileostomy may also be performed in order to achieve complete or near complete cytoreduction (Stamou et al, 2003).…”

Section: Resection Of Other Organsmentioning

confidence: 99%

Combined Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for the Treatment of Advanced Ovarian Cancer

Tentes¹,

Courcoutsakis²,

Prasopoulos³

2012

Ovarian Cancer - Clinical and Therapeutic Perspectives

View full text Add to dashboard Cite

Total abdominal colectomy, pelvic peritonectomy, and end‐ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non‐gynecologic cancer

Cited by 11 publications

References 16 publications

Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer

Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer

Peritoneal surface oncology: review of a personal experience with colorectal and appendiceal malignancy

Combined Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for the Treatment of Advanced Ovarian Cancer

Contact Info

Product

Resources

About